KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Other Non Operating Income (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Other Non Operating Income readings, the most recent being $3.5 million for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 94.3% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.9 million, a 91.11% decrease, with the full-year FY2025 number at $3.5 million, down 56.49% from a year prior.
  • Other Non Operating Income hit $3.5 million in Q4 2025 for Esperion Therapeutics, up from $677000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $61.2 million in Q4 2024 to a low of -$1.3 million in Q4 2022.
  • Median Other Non Operating Income over the past 5 years was $874500.0 (2025), compared with a mean of $4.7 million.
  • Biggest five-year swings in Other Non Operating Income: soared 16312.5% in 2021 and later plummeted 132.93% in 2022.
  • Esperion Therapeutics' Other Non Operating Income stood at $3.9 million in 2021, then plummeted by 132.93% to -$1.3 million in 2022, then surged by 507.94% to $5.3 million in 2023, then soared by 1057.1% to $61.2 million in 2024, then crashed by 94.3% to $3.5 million in 2025.
  • The last three reported values for Other Non Operating Income were $3.5 million (Q4 2025), $677000.0 (Q3 2025), and $666000.0 (Q2 2025) per Business Quant data.